Milestone Scientific MLSS
- Market cap
- $27.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $9.4M
- +4% on a year ago
- Net margin
- −44.0%
- Free cash flow yield
- −2.4%
Milestone Scientific trades at 2.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $9.4M over the last twelve months, up 4% on a year earlier with a −44% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.1M−7% | $2.3M+1% | $2.2M−13% | $1.9M−36% | $2.5M+22% | $2M−11% | $2.2M−1% | $2.3M+25% | $2.4M−6% | $2.1M+2% | $2.2M−3% | $2.8M+22% | |
| Cost of revenue | $555.9K−27% | $750.1K−35% | $572.7K−19% | $442.6K−57% | $677.6K+22% | $502.5K−33% | $585K+2% | $705.9K+60% | $719.2K+6% | $556.3K+11% | $598K+2% | $930.9K+32% |
| Gross profit | $1.5M+4% | $1.5M+39% | $1.7M−11% | $1.4M−25% | $1.8M+22% | $1.5M+0% | $1.6M−2% | $1.6M+15% | $1.6M−11% | $1.5M−1% | $1.6M−5% | $1.9M+18% |
| R&D | $170.5K+3% | $176.9K−30% | $94.2K−33% | $315K+47% | $232.1K+36% | $217.5K+23% | $369.1K+292% | $51.8K−84% | $16.2K−93% | $12.3K−94% | n/a | $6.6K−87% |
| SG&A | $2.8M−14% | $3.3M+17% | $3M−1% | $2.9M−27% | $3.1M+9% | $3.3M+1% | $3.3M+7% | $3M+6% | $2.7M−11% | $2.5M−23% | $2.4M−27% | $2.9M−3% |
| −$1.5M−25% | −$2M−2% | −$1.5M+9% | −$1.8M−22% | −$1.5M−3% | −$2M+3% | −$2M+36% | −$1.5M−17% | −$1.1M−23% | −$1.1M−47% | −$828.1K−59% | −$1.1M−29% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$1.5M−26% | −$2M−2% | −$1.4M+9% | $223.6K | −$1.5M−1% | −$2M+4% | −$2M+39% | −$1.5M | −$1.2M−21% | −$1.1M−46% | −$839.9K−58% | −$1.1M−29% |
| $0 | $0 | $0 | $0 | n/a | n/a | n/a | $0 | n/a | n/a | n/a | n/a | |
| Net income | −$1.5M−26% | −$1.9M−2% | −$1.4M+10% | $223.6K | −$1.5M−0% | −$2M+5% | −$2M+39% | −$1.5M | −$1.2M−21% | −$1.1M−46% | −$839.9K−58% | −$1.1M−29% |
| n/a | n/a | n/a | $0.00 | −$0.02 | −$0.03 | −$0.02 | −$0.02 | −$0.01−50% | −$0.01−67% | −$0.01−50% | −$0.01−50% | |
| n/a | n/a | n/a | 80M+11% | 80M | 78.7M | 81.9M | 82M+3% | 82.3M+3% | 82.2M+5% | 85M+4% | 93.1M+14% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13 and Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Milestone Scientific's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MLSSMilestone Scientific | $27.1M | n/m | n/a | 2.9× | +4% | −44.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| Peer median | $94.9M | 15.1× | 16.6× | 1.9× | +6% | 8.4% |
More on Milestone Scientific
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .